undervalued stocks

We think it’s +53 Bcf for this week’s storage report.

We are keeping our estimate unchanged for the week. If storage injections come in around our figure, year-over-year surplus will decrease by another 43 Bcf. Looking at our current projections, the year-over-year surplus will go away completely by Oct. 14 and go into deficit in the following weeks.

There are several additional things we want to highlight here. Storage in Eastern Canada is skidding the lines on capacity. Looking at our models, it’s clear to us that storage levels were going to make to EOS fine, but we guess for precautionary measures, gas imports to the U.S. ramped up yesterday.

A recent comment by Blacksaleem had particular insight into the situation. U.S. production dropped 0.8 Bcf/d, while Canadian gas imports ramped up 0.8 Bcf/d – completely offsetting one another. What we think is happening is what Blacksaleem said in his comment. U.S. gas production is now being curtailed to make room for natural gas from Eastern Canada, and producers are forced to cut back.

undervalued stocks: Google Inc.(GOOG)

Advisors’ Opinion:

  • [By Chris Neiger]

    Or perhaps you’ve heard of a Nest programmable thermostat.Alphabet(NASDAQ:GOOG) (NASDAQ:GOOGL)owns Nest, which makes internet-connected thermostats that you can control via a smartphone or tablet, and learns your heating and cooling preferences the more you use it.

  • [By Chris Neiger]

    For the mobile side, Alphabet’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google has already released several iterations of its Cardboard headset, and recently released its new Daydream View headset. These allow users to use their own smartphones to power a VR device.

  • [By Adam Levy]

    Google recently released a device similar to Echo, Google Home, in order to take advantage of the trend. Additionally, the Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL) subsidiary said voice searches tripled over the last two years.

  • [By Daniel Sparks]

    With Google parentAlphabet’s (NASDAQ:GOOG) (NASDAQ:GOOGL) fourth-quarter report now behind it, the company’s robust revenue growth and its promising traction in hardware and cloud-computing are getting some time in the spotlight. But there’s one other item in the company’s most recent quarterly report investors may want to take the time to consider: A key change in the way Alphabet will be calculating its non-GAAP results.

  • [By WWW.THESTREET.COM]

    “You want to buy companies that are leading in those sectors,” he said. “Companies like Google (GOOG) (GOOGL) , Facebook (FB) and Amazon (AMZN) are leading here. Most of these stocks haven’t priced in a stream of income or revenue from new products just yet.”

  • [By Shanthi Rexaline]

    Among the others in the fray are Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL), with a market cap of $650.77 billion, Microsoft Corporation (NASDAQ: MSFT) ($536.62 million) and Facebook Inc (NASDAQ: FB) ($433.95 million).

undervalued stocks: Genuine Parts Company(GPC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Aflac (AFL) — yielding 2.5%
    Archer-Daniels Midland (ADM) — yielding 2.7%
    Chevron (CVX) — yielding 3.8%
    ExxonMobil (XOM) — yielding 3.6%
    Genuine Parts (GPC) — yielding 2.7%
    Johnson & Johnson (JNJ) — yielding 2.8%
    T. Rowe Price (TROW) — yielding 3.2%

  • [By Lee Samaha]

    Genuine Parts Company (NYSE:GPC), owner of NAPA Auto Parts, became the first of the major auto parts companies to report earnings and sales for its first-quarter period ending on March 21.

  • [By ]

    After delivering 9% (including dividends) since my recommendation, shares of Genuine Parts Co. (NYSE: GPC) now trade at an attractive 15% discount to their 52-week high. Despite the rise and sudden drop, my original investment thesis is still intact.

undervalued stocks: Veeva Systems Inc.(VEEV)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Elite Opportunity Pronewsletter suggested mid cap global life sciencescloud-based software solutions stock Veeva Systems Inc (NYSE: VEEV) as a bullish long trade for investors who have patience:

  • [By Brian Stoffel]

    Last week, management at Veeva Systems (NYSE:VEEV) reported earnings that investors have become accustomed to. In fact, shareholders have been downright spoiled: both the top and bottom lines came in ahead of expectations; annual sales growth from Veeva’s non-CRM division came in at a blistering 113%.

  • [By Brian Stoffel]

    To say that Veeva Systems (NYSE:VEEV) has performed well as a publicly traded company would be an understatement. While the stock itself is actually down since its post-IPO days, the company’s fundamentals have vastly improved during that time frame.

undervalued stocks: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

undervalued stocks: Internap Network Services Corporation(INAP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 28 percent to $2.32 as the company reported that it has raised $43 million in a common equity private placement.

  • [By Lisa Levin]

    Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 13 percent to $2.97 on strong quarterly results. Stifel Nicolaus upgraded Internap from Hold to Buy and raised the price target from $2.00 to $5.50.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

Leave a Reply

Your email address will not be published. Required fields are marked *